Mutant selective JAK2V617F JH2 inhibitors that bind in the deep pocket
About
A seasoned team experienced in developing cancer medicines to create a fully integrated oncology company.
Mutant selective JAK2V617F JH2 inhibitors that bind in the deep pocket